Immunai

Company Overview

Snapshot

Founded in January 2019 by Noam Solomon, Luis Voloch, and Ansuman Satpathy, Immunai operates with 51–200 employees. The company has raised a total of $295,000,000 across 3 funding rounds from 14 investors. In October 2021, Immunai announced a $215 million Series B round led by Koch Disruptive Technologies.

Business overview

Immunai specializes in Health Tech & Life Sciences, developing a proprietary dataset of multi-omic, immune-centric peripheral tissue analyses. The company's core technology leverages advanced analytics and a data-visualization interface to enable researchers to comprehensively view and interrogate data, deriving novel conclusions on underlying disease mechanisms. Immunai's platform is currently utilized to develop and refine cell therapies, serving the pharmaceutical and healthcare industries by enhancing drug discovery and development, particularly in areas like oncology and immunology.

Strategic signal

In June 2026, Immunai announced a collaboration with Boehringer Ingelheim to decode T-cell dysfunction, a critical factor in both cancer and autoimmune disorders. This partnership highlights Immunai's continued strategic validation within the pharmaceutical industry, demonstrating the utility of its AI-based immune system modeling platform for addressing complex biological challenges and accelerating drug development in significant therapeutic areas.

Company Intelligence Q&A

What was a significant recent partnership for Immunai?

In June 2026, Immunai announced a collaboration with Boehringer Ingelheim to focus on decoding T-cell dysfunction, which is implicated in both cancer and autoimmune disorders.

What was Immunai's most recent funding round?

In October 2021, Immunai announced a $215 million Series B funding round, led by Koch Disruptive Technologies.

What was Immunai's first acquisition?

In March 2021, Immunai acquired Dropprint Genomics to strengthen its leadership team with immunology experts and expand its target discovery capabilities.

What is the focus of Immunai's collaboration with Teva?

In November 2024, Immunai and Teva launched a multi-year AI collaboration aimed at enhancing precision in immunology and oncology trials by utilizing Immunai’s immune system mapping tools.

What is the strategic importance of Immunai's partnership with Baylor College of Medicine?

Immunai's platform is being used in conjunction with the Baylor College of Medicine to develop and refine cell therapies for neuroblastoma, showcasing its application in critical therapeutic areas.